About this trial
Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan).
The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.
Eligibility criteria
Qualifiers
Age 18 years or older
On optimal medical therapy for heart failure
NYHA class II to IV
Left ventricular ejection fraction (EF) ≤ 35%
Disqualifiers
Co-morbidities likely to reduce life expectancy to less than 6 months
Major cardiovascular event within the past 6 weeks
More than mild aortic stenosis
Receiving continuous or intermittent infusion therapy for heart failure
Trial design
Treatments tested in this trial
- EF1 guided CRT optimisation
- Standard of Care (SOC)
Treatment groups
Sponsors and collaborators
King's College London
Lead sponsor
Guy's and St Thomas' NHS Foundation Trust
Collaborator
The Leeds Teaching Hospitals NHS Trust
Collaborator
King's College Hospital NHS Trust
Collaborator
Barts Helth NHS Trust
Collaborator